Skip to main content
Premium Trial:

Request an Annual Quote

Olink Reorganizes, Splits Into Two Companies

NEW YORK (GenomeWeb) – Olink AB announced today that it has completed a reorganization and has split into two separate companies — Olink Proteomics and Olink Bioscience.

Olink Proteomics will continue to expand and develop the Proseek Multiplex human protein biomarker discovery product portfolio and is aiming to create a variety of high-quality multiplex immunoassays for biomarker discovery as well as diagnostic tools based on clinically relevant protein signatures.

Proseek Multiplex is based on the company's proprietary Proximity Extension Assay technology, a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules, which give rise to new DNA amplicons, according to the company. The amplicons are subsequently quantified by high-throughput, real-time PCR.

Olink sold its Duolink product portfolio to Sigma-Aldrich in October in order to refocus its efforts on the Proseek Multiplex.

Olink Bioscience will focus on developing and commercializing the other technologies in the company's IP portfolio. Its R&D team is collaborating with scientists at Uppsala University to develop new molecular tools for life science researchers and for molecular diagnostics.

"The company division reflects both the desire to best serve the needs and expectations of customers in our rapidly growing Proseek business, and the deep-seated commitment to develop exciting new molecular tools for the wider scientific community," Andrea Ballagi, VP of sales and marketing at Olink Proteomics, and Olink Bioscience CEO Peter Åsberg said in a statement.

Lotta Falck will serve as CEO for Olink Proteomics. Both companies are headquartered in Uppsala, Sweden.